

FCDS AUGUST/September 2002 MONTHLY MEMO

FCRA/FCDS COMBINED ANNUAL CONFERENCE



FCDS would like to thank all of the health professionals and guests who attended the 2002 FCRA/FCDS Annual Conference, "Keeping Up With Change" The conference was held at the Hyatt in Sarasota, Florida, July 31—August 2, 2002.

Conference objectives included: providing information on Issues and Updates, recent Technical Issues and the new reporting Clinical Laboratory Identification Program; clinical research strategies concerning the detection and treatment of certain cancers; providing information on cancer control and prevention strategies and initiatives in the state of Florida; reviewing recent epidemiological research that uses population-based cancer surveillance data; providing information regarding the 2002 reporting requirements for the United States and Florida; and, enhancing the technical skills of cancer registrars and abstractors relating to the process of cancer data collection.

FCDS would like to thank the FCRA program chair Jamie Suarez and the 2002 Program Committee for their tremendous effort in putting together a timely and informative educational conference again this year.

FCDS would also like to announce that starting next year our annual conferences will again be split into two back-to-back but separate meetings. FCDS will host its annual meeting on the first of three continuous days of meetings. FCRA will host a two-day conference the following days. Conference fees will be paid separately. The fee for the FCDS conference will be \$25.00. FCRA will announce conference fees for their two-day meeting at some point in the future. The next annual meeting will be held in Clearwater, Florida, July 30-August 1, 2003. Again, FCDS will hold its annual meeting on Wednesday July 30th, 2003, and FCRA will hold its meeting July 31 - August 1st, 2003.

FCDS EDUCATIONAL TELEPHONE CONFERENCE

FCDS EDUCATIONAL TELEPHONE CONFERENCE

Topic: Understanding & Coding Cancer Treatment



OBJECTIVE: The telephone conference will provide registrars, abstractors and contractors with a review of the 2003 requirements for coding cancer treatment as well as a thoughtful review of treatment concepts and terminology pertinent to cancer registrars. There will be sufficient time during the call to address any treatment-related questions or concerns by registrars.

A PowerPoint slide presentation will be available on both the FCDS and FCRA websites on October 1, 2002

<http://www.fcds.med.miami.edu>—Downloads Page . We suggest that you download the presentation and follow the slideshow from your computer during the call. You may also print the slideshow for future reference. If for some reason you do not have access to the FCDS website, you may contact FCDS and we will mail or fax you a copy of the slideshow. Please do not wait until the last minute to request mailed or faxed copies of the slides.

CALL IN INFORMATION:

Date of Conference: **October 16, 2002**

Time of Conference: **2pm – 3pm EDT**

Name of Conference: ***Understanding & Coding Cancer Treatment – 2003 Reporting Requirements***

Telephone Number: **(877) 214-0402**
(This is a Toll-Free Number)

Call-in Code: **330892**

This is the fourth telephone conference in the FCDS 2002 series. FCDS is pleased to provide this type of phone-in educational format as a standard method for delivering new information and providing hands-on training to registrars and other parties interested in cancer information management issues throughout the state of Florida. Suggestions for future topics are encouraged. Please submit suggestions to FCDS by phone at 1-800-906-3034 or by e-mail to Jill_MacKinnon@miami.edu.



**ANNOUNCING ANOTHER...
PATHOLOGY EDUCATIONAL
TELEPHONE CONFERENCE**

Topic: Update on the New FCDS
Clinical Laboratory
Cancer Identification
Program.

Date: October 29, 2002

Time: 2pm-3pm

OBJECTIVE: The telephone conference will provide an update to the clinical pathology laboratory administrators, registrars, abstractors and contractors with an overview of the new Clinical Laboratory Cancer Identification Program. The conference will cover reporting legislation, reporting requirements, details for case identification, details for the data elements required for case submission, details for data submission via the FCDS IDEA (Internet data transmission protocol) and other related subjects. There will be sufficient time during the call to address any questions or concerns by path lab administrators and registrars.

A PowerPoint slide presentation will be available on the FCDS Website on October 15, 2002 as an adjunct to the conference (<http://www.fcds.med.miami.edu>). We suggest that you download the presentation and follow the slideshow from your computer during the call. You may also print the slideshow for future reference. If for some reason you do not have access to the FCDS website, you may contact FCDS and we will mail or fax you a copy of the slideshow. Please do not wait until the last minute to request mailed or faxed copies of the slides.

CALL IN INFORMATION:

Date: October 29, 2002

Time: 2pm – 3pm EST

Name: Clinical Laboratory
Cancer Identification Program

Phone: **877.300.8186**

(This is a Toll-Free Number)

Call-in Code: **549450**

Coding Complex Morphologies in ICD-O-3

The following has been provided with permission from April Fritz, RHIT, CTR and the Michigan Cancer Surveillance Program Newsletter– July 2002 Update. SEER held a workshop in Detroit on April 11-12, 2002. For questions please contact April at fritz@nih.gov.

What is the answer for the following questions:

1. Ductal carcinoma in situ (DCIS), micropapillary and cribriform types
2. Intraductal carcinoma, showing papillary differentiation.
3. Duct carcinoma in situ, cribriform with central necrosis (comedocarcinoma), high nuclear grade.
4. Infiltrating duct carcinoma, tubular type, low grade.
5. Infiltrating duct (scirrhous type) with small focus of DCIS (cribriform with central necrosis). Grade: histologic 3, nuclear 3.
6. Infiltrating ductal carcinoma, papillary type; ductal carcinoma in situ, cribriform type, modified Bloom-Richardson score: 3

Answers to the above Coding Complex Morphologies in ICD-O-3 questions:

1. *Code morphology as: 8523/29*
Explanation: Two types of DCIS—use ductal combination code; change behavior to in situ.
2. *Code morphology as: 8503/29*
Explanation: Code to single entity papillary duct carcinoma.
3. *Code morphology as: 8523/24*
Explanation: Two types of DCIS—use ductal combination code; change behavior to in situ; high nuclear grade = 4.
4. *Code morphology as: 8211/32*
Explanation: Single type of duct carcinoma; low grade (NOS) = 2.
5. *Code morphology as: 8141/33*
Explanation: Code invasive component (scirrhous adenocarcinoma); histologic grade 3= 6th digit 3.
6. *Code morphology as: 8503/31*
Explanation: Papillary ductal carcinoma is a specific type; BR score translates to 6th digit 1.

HIPAA Compliance Concerns

<http://www.ncra-usa.org/announce.html>

The Administrative Simplification Compliance Act allowed covered entities to request a one year extension to the compliance deadline - until Oct 16, 2003, by submitting a compliance plan to the Department. The compliance plan MUST be submitted by October 15, 2002.

CMS has developed the HIPAA Model Compliance Plan to meet that need & can be submitted electronically.

CoC I&R FAQs	CoC Member Organizations in NAACCR
<p>Q: Is there a time limit for physicians to complete either clinical or pathologic AJCC staging?</p> <p>A: The clinical staging time frame ends when the patient receives the first treatment or when a decision is made not to treat. The pathologic classification is based on the evidence acquired before treatment, supplemented, or modified by the additional evidence acquired from surgery and from pathologic examination. The pathologic time frame ends after the most definitive surgery and uses information from the surgery and pathology report. If the physician chooses to restage after treatment, the "y" prefix must be used.</p> <p>Q: If a patient is seen at our facility for a biopsy ONLY is AJCC staging still required?</p> <p>A: AJCC staging is required for all analytic cases (Class of Case 0, 1, and 2). For cases where only a biopsy is performed at the reporting facility, the physician should stage the case at that point in time. At the time of the biopsy, unknown stage may be the correct information. If so, it should be recorded in the medical record by the managing physician. If the physician knows that the patient will be returning in a short time for definitive treatment, then staging can be done at that time. The physician should note this information on the initial staging form.</p>	<p>The North American Association of Central Cancer Registries (NAACCR) has been a member of the Commission on Cancer since 1996. Their current representative is Rosemary Dibble, CTR, from the Utah Cancer Registry in Salt Lake City, UT.</p> <p>NAACCR is a professional organization that develops and promotes uniform data standards for cancer registration, provides education and training, certifies population-based registries, aggregates and publishes data from central cancer registries, and promotes the use of cancer surveillance data and systems for cancer control and epidemiological research, public health programs, and patient care to reduce the burden of cancer in North America.</p> <p>Collaborations with the CoC exist through representatives of both groups serving as board members, committee members, liaison representatives, and special interest groups. Andrew Stewart, Manager of the National Cancer Data Base Analytic Unit, currently serves as chair of NAACCR's Uniform Data Standards Committee, which is responsible for promoting uniformity of data items and definitions collected by various cancer data gathering organizations. Susan DesHarnais, PhD, Scientific Director for the National Cancer Data Base, is collaborating on a study of racial disparities in breast cancer care, and Connie Blankenship, Administrative Director for Cancer Programs, represents the CoC and the AJCC on the NAACCR Board. Additional collaborative initiatives with NAACCR include work on the Collaborative Stage Project, and studying the implications of HIPAA for the entire surveillance community. We invite you to learn more about NAACCR by visiting their Web site at http://www.naacr.org.</p>
<p>New CoC ROADS to FORDS Conversion Tool Kits Available</p>	<p>Minor Corrections to FORDS Online</p>
<p>The ROADS to FORDS Conversion Tool Kits that are now available for registry software providers. The tool kit is designed to support the technical development of tools required to transition registries from ROADS to FORDS. It includes the conversion rules necessary to implement the changes introduced with the publication of FORDS as well as the computerized conversion code which translates NAACCR Volume 9.1 to Volume 10 following the specifications described in the ROADS to FORDS conversion rules. A copy of the executable conversion program as well as the published conversion rules are available on CoC Web site: http://www.facs.org/dept/cancer/</p>	<p>Several typographical errors have been identified in the coding instructions for the following FORDS data items: Surgical Margins of the Primary Site (p.137), Scope of Regional Lymph Node Surgery (p.138), Scope of Regional Lymph Node Surgery at this Facility (p.140), and Specific Surgery Codes, Appendix B (p.266 and 284). In addition, the site definition for hematopoietic diseases and meninges appearing in the Site-Specific Surgery Codes, Appendix B has been clarified (p.265) and corrected (p.281), respectively. CoC has revised the appropriate PDF files on their web site at http://www.facs.org/dept/cancer/coc/fordsmanual.html. There is also an individual PDF that holds just the corrected pages.</p> <p>If you have already printed or purchased a copy of the FORDS manual, we encourage you to replace the current pages with those found in the PDF with just the corrected pages. For those who have downloaded the manual from the Web to your desktop, we suggest you replace your current files with the revised PDFs for the sections First Course of Treatment and Appendix B or the single, complete FORDS file.</p>



**2003
NAACCR Annual
Meeting**

When:
June 8-14, 2003

Where:
Honolulu, Hawaii

For more information go to:
<http://www.naacr.org/News/files/AnnualMeeting2003.pdf>

New Atlas of Sentinel Lymph Node Mapping Available

Stanley P. L. Leong, MD, FACS, a member of the American Joint Committee on Cancer and Liaison To the Commission on Cancer, is Editor of the new reference, "Atlas Of Selective Sentinel Lymphadenectomy For Melanoma, Breast Cancer And Colon Cancer.

This text emphasizes the multidisciplinary approach to combining the experiences of a nuclear medical physician, surgeon, and pathologist. Published in July 2002

The atlas is available from Kluwer Academic Publishers

Call toll free at 1-866-269-WKAP (North American orders only)

Ambulatory Care Centers Cancer Reporting Program

On June 17, 2002, FCDS completed the matching of the year 2000 ambulatory patient care encounters reported by Florida Ambulatory Care Centers' to the Agency for Health Care Administration (AHCA). All records with principal or secondary diagnoses of cancer were linked to the FCDS database. Only records reported to AHCA but not matched to an FCDS record will appear on the lists titled "AHCA Ambi Unmatched Cancer Records Request."

On June 18, 2002, FCDS mailed out the "AHCA Ambi Unmatched Cancer Records Request" lists for 2000 to the Florida Ambulatory Care Centers. The 2000 listings included ambulatory patient care encounters occurring between January 1, 2000 and December 31, 2000. **The centers will only receive notification for cases that have never been reported from any other cancer reporting source to FCDS.**

Facility with fewer than 35 cancer cases:

Any facility with fewer than 35 cancer cases identified on the "AHCA Ambi Unmatched Cancer Records Request" list need only submit copies of patient records to FCDS for each of the cases on the list. FCDS will do the abstracting. A Batch Transmittal Form must be included with any chart copies submitted.

The following reports (if available) from each patient record must be submitted before August 31, 2002: Face sheet, Summary, History & Physical, Operative Reports, Consultation Reports, Pathology Reports, Radiology Reports, Laboratory Reports and all other pertinent reports.

Facilities with 36 or more cases:

FULL CASE REPORTING REQUIRED FOR ALL FACILITIES WITH 36 OR MORE CANCER CASES LISTED ON THE "AHCA AMBI UNMATCHED CANCER RECORDS REQUEST":

EACH CASE MUST BE REVIEWED. The facility must determine whether or not each of the identified case records must be reported to the FCDS by referring to the FCDS reporting criteria outlined in Section I of the *FCDS Data Acquisition Manual*. If the case meets the FCDS reporting criteria, a full case abstract must be submitted to FCDS before August 31, 2002. All data submitted to FCDS must be via the encrypted Internet transmission, FCDS IDEA. For further information, visit the FCDS website at <http://fcds.med.miami.edu>. If the case does not meet the FCDS reporting criteria, the appropriate Disposition Code must be documented on the "AHCA Ambi Unmatched Cancer Records Request" list and returned to FCDS before August 31, 2002.

DRUG BULLETIN UPDATES



The U.S. Pharmacopeia (USP) has accepted the following new off-label indications in September 2002. The following new drugs are for palliative care only and should not be coded as treatment. **Darbepoetin alfa** for chemotherapy-induced anemia dosed every two weeks

Rituximab for the treatment of immune or idiopathic thrombocytopenic purpura

TOP ONCOLOGY NEWS

The Food and Drug Administration (FDA) announced the approval of Eloxatin (oxaliplatin) injection for use in combination with infusional 5-fluorouracil (5-FU) and leucovorin for the treatment of patients with colorectal cancer whose disease has recurred or become worse following initial therapy with a combination of irinotecan with bolus 5-FU and leucovorin. The combination including Eloxatin was shown to shrink tumors in some patients and delay resumed tumor growth. There are as yet no data on the effects of the combination on survival.

USP's updated database of oncology and supportive care drugs are available on ACCC's web site at www.accc-cancer.org. Click on the "Oncology Drugs" button; then sign in. The database is updated monthly.



FDA APPROVED ONCOLOGY AGENTS NOT LISTED IN SEER BOOK 8

SEER has recently made available a 4-paged table that lists numerous chemotherapy, hormonal therapy, immunotherapy, radiotherapy and ancillary drugs that have been approved as cancer treatment agents since the printing of SEER Book 8.

Please download your copy of this table from either the SEER website or the FCDS website.
Do it TODAY !!!

JEAN BYERS AWARD

In accordance with national standards for evaluating completeness, FCDS will be revising the procedures for awarding the Jean Byers Award for Excellence in Cancer Registration. Please do not submit the Jean Byers Application. Details were announced at the recent FCRA/FCDS 2002 Annual Meeting.

AFFIDAVIT OF COMPLETENESS

FCDS has decided to do away with the process of having registrars sign an Affidavit of Completeness to attest to the completion of the reporting of their cancer cases after the end of the reporting year. Different methods of verifying completeness are currently being developed by FCDS.

2003 NCRA 29th Annual Education Meeting in Pittsburgh, PA -- May 13-16, 2003

Call for Presentations—Submit a presentation Share your expertise by bringing important information to your peers. <ftp://ncra-usa.org/pub/CallforPresentations.pdf>

For the convention information visit: <http://www.pgh-conventionctr.com/html/introduction.html>

Education & Training

SEER's Training Web Site - <http://seer.cancer.gov>

The SEER website is a great educational resource for the new registrar/abstractor as well as the experienced registrar. SEER recently introduced several new web-based training modules on their website with two final modules under development. When the site is completed it will contain over 12 individual training modules, each covering a particular area of cancer registration.

The following SEER training modules are currently available:

SEER TRAINING MODULES

- ICD-O-3
- SEER Summary Stage 2000
- Cancer Registration
- Cancer Treatment
- Cancer as a Disease
- Casefinding
- Anatomy & Physiology
- Diagnostic Test
- Coding of primary site & Tumor Morphology
- Abstracting a Cancer case
- Staging a Cancer Case
- Cancer Patient Follow-up **coming soon!**
- Cancer Registry Operations & Procedures **coming soon!**

INFORMATIONAL MODULES

- ICD-O-3 Satellite Training Video
- Summary Staging 2000 Manual

Stay Tuned to the SEER website for New Education and Training Enhancements over the year.

ORDER YOUR COPY

SEER Abstracting & Coding Guide for Hematopoietic Diseases

SEER Program Training Materials
National Cancer Institute
<http://www.seer.cancer.gov>
May 2002

Quarterly Activity Report

The Third Quarterly Activity Report for 2002 will be mailed to facility administrators and registrars sometime in early September 2002.

The report consists of two sections. The Quarterly Activity Summary reflects the FCDS file activity and data submissions for each facility on a quarterly basis. It highlights information about the total number of cases submitted and the quality of the data (good and failed cases). FCDS requires that inpatient facilities submit data at least every quarter; monthly data submission is recommended for any facility with an annual caseload greater than 500. Thus, all facilities should show some file activity every quarter. The Annual Case Summary reflects all cases submitted to FCDS by the facility during the past four reporting years. Please contact Meg Cuadra at (305) 243-2625 should you have any questions about the report.

GENERAL MAILING INSTRUCTIONS TO FCDS:

In order to protect and properly handle all packages, particularly those containing confidential patient information, we ask that US Postal Service mail including Express mail, Priority mail, and Certified mail be sent to FCDS via the PO Box address below:

FCDS/ University of Miami
School of Medicine
PO BOX 016960 (D4-11)
Miami, FL 33101

FCDS street address should only be used for Courier packages (Federal Express, UPS, Airborne Express).

FCDS/University of Miami
School of Medicine
1550 NW 10 AVE, Room 410
Miami, FL 33136


<p>CASEFINDING</p>	<p>AJCC Cancer Staging Manual 6th Edition Videoconference, November 21, 2002</p>
<p>Malignant Terms That Don't Sound Like Malignancies</p> <p>Ref: http://training.seer.cancer.gov/module_icdo3/</p> <p>There are a number of diagnoses that are malignant and reportable but do not sound that way.</p> <p>Atypical carcinoid</p> <p>SETTLE, CASTLE</p> <p>Rhabdoid tumor, NOS</p> <p>Intratubular germ cell neoplasia</p> <p>Epithelioid trophoblastic tumor</p> <p>Mixed pineal tumor, transitional pineal tumor</p> <p>Atypical teratoid/rhabdoid tumor</p> <p>Pagetoid reticulosis</p> <p>Generalized Langerhans cell histiocytosis</p> <p>Agnogenic myeloid metaplasia</p> <p>Acute progressive histiocytosis X</p> <p>Heavy chain disease</p> <p>Immunoproliferative small intestinal disease</p> <p>Hypereosinophilic syndrome</p> <p>Therapy-related myelodysplastic syndrome</p>	<p>The American Joint Committee on Cancer (AJCC) will sponsor a two-hour videoconference for physicians and cancer registrars titled "The Changing Strategies of TNM Staging: Introduction to the AJCC 6th Edition." The videoconference is scheduled for Thursday, November 21, 2002, and will be broadcast in four time zones. The AJCC will be able to accommodate facilities in Puerto Rico and Hawaii.</p> <p>The videoconference will address the purpose and need for staging, general staging rules, common errors in staging, and changes in the AJCC Cancer Staging Manual 6th Edition for the major cancer sites and those with extensive revision.</p> <p>For further details on how to participate please go to the Education section of the AJCC Web site at http://www.cancerstaging.org.</p> <p>If you require additional information, contact Susan Burkhardt, AJCC Administrator, at 312/202-5313 or sburkhardt@facs.org.</p>
	<p>SAVE 30% On your AJCC Staging Manual & Handbook - 6th Ed.</p> <p>NCRA is glad to offer a new convenient link to Barnes and Noble Bookstore through the NCRA website. Take advantage of the limited-time offer of 30% SAVINGS on American Joint Committee on Cancer's Cancer Staging Manual and Handbook, 6th Edition!</p> <p>Free shipping is also offered if you purchase 2 or more items!!</p> <p>Anytime you are shopping for a book, click through to the Barnes and Noble Bookstore from the NCRA website external links page.</p>
	<p style="text-align: center;"><u>Collaborative Stage (CS) Data Set</u> <u>Implementation Statement</u></p> <p>http://www.cancerstaging.org/dataset.html</p> <p>A decision has been made by the CS Task Force and sponsoring organizations to delay the implementation of the CS Data Set until January 1, 2004. The CS Data Set is a completely new approach to data collection and collaboration among the major standard-setting organizations, and the delayed implementation will allow for the production of a high quality product. This additional time will also enable us to fully proof the disease-site data sets against the AJCC Sixth Edition, to produce and publish a coding manual, to complete and test the computer algorithm, to incorporate CS into registry software, and to prepare for training in multiple mediums including on-site presentations, video conferences, and on the Internet. The delay of CS will <i>not</i> impact the January 1, 2003 implementation date for the Commission on Cancer's <i>Facility Oncology Registry Data Standards (FORDS)</i> or the <i>AJCC Cancer Staging Manual, Sixth Edition</i>. Questions and comments can be directed to Valerie J. Vesich, AJCC technical Administrator, at (312) 202-5435 or e-mail at vvesich@facs.org.</p>



2003 CTR
EXAM

Due to changes in the management of the examination process by NCRA, information on 2003 examinations will not be available until later this year. **Visit the NCRA Website for Important Testing Information:** <http://www.ncra-usa.org>.

For future CTR exam information please contact:
 Lori Swain, Executive Director, NCRA
 1310 Braddock Place, Suite 102
 Alexandria, VA 22314
 703-299-6640; 703-299-6620 - fax

<p>Education & Training</p> <p>We're on the Web! FCDS.med.miami.edu</p>	<p><u>FCRA REGIONAL WORKSHOP</u> <u>October 19, 2002</u></p> <p>On October 19, 2002, there will be a FCRA Regional Workshop on Who, Why, What and How on the new FORDS—Facility Oncology Registry Data Standards manual. Jointly offered by the Florida Cancer Registrars Association and the American College of Surgeons, Commission on Cancer at Orlando Regional Medical Center, Room MPR A, 1414 S. Orange Avenue, Orlando, FL. Registration fee: \$30, lunch included, class limit: 45 participants. CE credits applied for. For more information please contact: Patricia A. Bently, CTR: ph: 407-894-6232, fax 407-897-2232, e-mail: patbently@cfl.rr.com or Rosemarie E. Clive, LPN, CTR, PH: 407-677-0755, e-mail: rclive@cfl.rr.com.</p> <p><u>FCRA REGIONAL WORKSHOP</u> <u>Rescheduled for November 1, 2002</u></p> <p>The JUNE 28, 2002 FCRA Regional Workshop on GYN Malignancies which was to be held at Jackson Memorial Hospital, Miami, FL has been rescheduled for November 1, 2002.</p> <p>Jackson Memorial Hospital will sponsor the FCRA Regional Oncology Workshop at the JMH/ Diagnostic Treatment Center, Second Floor, Room 259 at 1900 NW 12 Avenue, Miami, FL on Friday, November 1, 2002 from: 8:00 a.m. to 1:00 p.m. Topic: Gynecological Malignancies. For more information contact: Lizette Acosta (305) 585-6533.</p> <p><u>FCDS INCIDENCE ABSTRACTING WORKSHOP, October 23-25, 2002</u></p> <p>FCDS conducts semi-annual workshops for incidence-only cancer case reporting. The three-day intensive course covers only the basics of cancer reporting for Florida.</p> <p>The October 23-25, 2002 workshop will cover all of the 2001 reporting requirements. The cost of this workshop is \$100.00. The workshop will be held at the Double Tree Inn in Coconut Grove, Florida.</p> <p>For more information please contact Bleu Herard 800-906-3034 / 305-243-4600 or Betty Fernandez.</p>	<p><u>Principles of Oncology for Cancer Registry Professionals</u> <u>December 2-6, 2002</u></p> <p>Principles of Oncology is an intensive five-day training program in cancer registry operations and procedures emphasizing accurate data collections, basic registry concepts, abstracting, staging, and ICD-O coding. Three volumes of training materials and the NCRA's Workbook for Staging of Cancer, 2nd edition will be provided to registrants.</p> <p>The program is suitable for oncology program employees (hospital-based and central registry) with minimal knowledge of cancer, anatomy, physiology, and medical terminology. Cancer registrars with less the one year of experience would benefit most from this program, however registrars with up to three years experience and registrars preparing for the CTR exam are welcomed to attend.</p> <p>For further info., please contact: April Fritz, RHIT, CTR, Training Program Coordinator, Data Quality Manager, SEER Program, 6116 Executive Blvd, Suite 504, National Cancer Institute, MS 8316, Rockville, MD 20852. Email: april.frtiz@nih.gov. Phone 301-402-1625, fax: 305-496-9949</p> <p><u>Principles and Practice of Cancer Registration, Surveillance, and Control, November 4-8, 2002</u></p> <p>Principles and Practice of Cancer Registrations, Surveillance, and Cancer Control will be held at the Emory University in Atlanta, Georgia November 4-8, 2002.</p> <p>A staff of recognized experts in cancer registration, surveillance, and cancer control teaches this intensive and comprehensive training program.</p> <p>The instructors are accomplished adult trainers and are internationally recognized as leaders in their fields.</p> <p>Complete details are available on the training program web site at http://cancer.sph.emory.edu or contact Steven Roffers, PA, CTR at (404) 727-4535.</p>
<p><u>FCDS NEXT Web-Teleconference:</u></p> <p><u>October 16, 2002</u> Understanding and Coding Cancer Treatment—2003 Reporting Guidelines. Slides will be available October 1, 2002.</p> <p><u>October 29, 2002</u> Update on the Florida Clinical Laboratory Cancer Identifications Program (CLIP) . Slides will be available October 15, 2002.</p> <p><u>FCDS Past Web-Teleconferences:</u></p> <p><u>June 26, 2002</u> Florida Clinical Laboratory Cancer Identification Program (CLIP). Slides as PowerPoint 2000 file with notes.</p> <p><u>June 5, 2002</u> ACCRP 2002—Ambulatory Centers Cancer Reporting Program Requirements for 2002. Slides as PowerPoint 2000 file with notes.</p> <p><u>February 21, 2002</u> Technical Expertise - Just a Click Away! - Web Tools and Resources for Everyday Abstracting. Slides as PowerPoint 2000 file with notes.</p> <p><u>November 14, 2001</u> Cancer Registry References Review - Part II of II. : FCDS Error Messages, FCDS Error Messages by Category, Slides, PowerPoint 2000 Slides.</p> <p><u>October 17, 2001</u> Cancer Registry References Review - Part I of II. Slides as PowerPoint 2000 file.</p> <p><u>August 8, 2001</u> FCDS Internet Data Entry, Abstracting and Data Submission Policies and Procedures. Slides as PowerPoint file.</p> <p><u>July 25, 2001</u> Administrative Issues in Florida Cancer Case Reporting. Slides as PowerPoint file.</p> <p><u>June 20, 2001</u> Surgery Coding, New Surgical Fields and SEER Summary Stage 2000. Selected pages from SEER manual, Surgery and Staging Notes. Slides as Power-point file.</p> <p><u>May 9, 2001</u> Florida Cancer Reporting and Implementation Strategies. Files used during the conference call: Staging Changes Summary, PowerPoint file.</p>		


- ★ Project Director
- ★ Edward J. Trapido, ScD
- ★ Administrative Director
- ★ Jill Mackinnon, CTR
- ★ Editorial Staff
- ★ Mayra Alvarez, RHIT, CTR
- ★ Steven Peace, CTR
- ★ Contributor
- ★ Mark Rudolph
- ★ Megsys Cuadra, CTR



667369



Florida Cancer Data System
University of Miami School of Medicine
P.O. Box 016960 (D4-11)
Miami, FL 33101



The QC staff is performing the every 25 from all facilities.

DEADLINES

HOSPITALS

Hospitals should now be reporting February 2002 cancer cases

AMBULATORY CENTERS CANCER REPORTING PROGRAM (ACCRP)

Ambulatory Centers AHCA 2000 patient encounters were DUE **August 31, 2002**

Hospital submissions for 2000 and 2001 cancer cases

